Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Filer submitted a Form 144 reporting proposed sales of common stock related to compensation vesting. The filing lists 16,314 shares under "Securities To Be Sold" with a date of 02/27/2026. It also records prior sales: 2,324 shares on 12/02/2025 and 4,209 shares on 12/03/2025.
The broker address shown is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI. The excerpt includes an NYSE listing and a numeric reference 178,396,434 alongside 03/02/2026.
Teladoc Health (TDOC) insider sale notice: a proposal to sell 50,145 common shares tied to restricted stock vesting on 02/27/2026 as compensation. The filing also records a prior sale of 17,138 common shares on 12/11/2025 by Charles Divita for $130,836.63.
TDOC submitted a Form 144 notice reporting 26,647 shares of Common stock associated with a restricted stock vesting event on 02/27/2026; the filing lists Fidelity Brokerage Services LLC as the selling broker and the exchange as NYSE. The filing notes a prior sale by Kelly Bliss of 4,582 shares on 12/02/2025 for $34,311.39.
Tdoc, Inc. filed a Form 144 disclosing a proposed sale of 27,083 common shares. The securities are described as Restricted Stock Vesting with a vesting/transaction date of 02/27/2026 and are listed as issuer/compensation-related.
The filing also reports prior sales of 5,720 common shares on 12/02/2025 by Adam Vandervoort. The notice names Fidelity Brokerage Services LLC as the broker and is tied to NYSE-listed common stock.
Carlos Nueno Plana filed a Form 144 to sell 20,165 common shares as restricted stock vests. The filing lists sale routing through Fidelity Brokerage Services LLC and notes the shares are tied to compensation and a vesting date of 02/27/2026. The filing also records a prior sale of 3,897 shares on 12/02/2025.
Teladoc Health outlines in its annual report how it operates a large-scale virtual care platform while remaining unprofitable. The company completed 17.1 million telehealth visits in 2025, serving approximately 102 million U.S. members across its Integrated Care and BetterHelp segments.
In 2025, Teladoc Health generated about 83% of consolidated revenue from recurring access fees, with the rest from visit fees and hardware and software for hospitals and health systems. It reported a net loss of $200.3 million for 2025 and an accumulated deficit of $16,430.2 million as of December 31, 2025, including non-cash goodwill impairments. The business depends heavily on a small group of large Clients, with the top five accounting for 19% of total revenue, and highlights regulatory, cybersecurity, competition, and privacy risks as key ongoing challenges.
Teladoc Health reported Fourth Quarter 2025 revenue of $642.3 million, roughly flat year-over-year, and a net loss of $25.1 million, or $0.14 per share. Adjusted EBITDA rose 12% to $83.8 million as Integrated Care offset softer BetterHelp performance.
For Full Year 2025, revenue declined 2% to $2.53 billion while net loss narrowed sharply to $200.3 million from $1.00 billion, helped by much lower goodwill impairments. Adjusted EBITDA fell 10% to $281.1 million. Operating cash flow was $294.4 million and free cash flow was $166.9 million. Guidance for 2026 calls for revenue of $2.47–$2.59 billion, adjusted EBITDA of $266–$308 million, and free cash flow of $130–$170 million, with Integrated Care growing modestly and BetterHelp expected to decline or remain roughly flat.
Smith Michael S reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Michael S. Smith received a grant of 53,648 restricted stock units, each representing the right to receive one share of TDOC common stock. One-third of these units vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. filed an initial insider ownership report for board member Michael S. Smith. This Form 3 filing establishes him as a reporting person under insider trading rules and provides the baseline disclosure of his existing relationship to the company as a director.
Teladoc Health expanded its board of directors and appointed Michael Smith as a new independent director, effective February 18, 2026. He was also named to the audit committee and the nominating and corporate governance committee, and is designated an “audit committee financial expert” under SEC and NYSE rules.
Smith brings more than three decades of experience in insurance and financial services, including senior roles at Voya Financial and Lincoln Financial, and currently serves as Executive Chairman of Talcott Financial Group. Teladoc Health also announced it will release fourth quarter 2025 results on February 25, 2026, followed by a conference call at 5:00 p.m. ET.